SCHEMBL5638974

SCHEMBL5638974

N[C@@H]1CCCCN(C(=O)Nc2ccc(F)cc2)C1=O

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.54
▸ ALDH1A1 P00352 2/20 0.52
▸ THRB P10828 2/20 0.49
▸ ALOX12 P18054 1/20 0.49
▸ RAB9A P51151 4/20 0.45
▸ NPC1 O15118 3/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ EPHX1 P07099 1/20 0.45
▸ MAPT P10636 1/20 0.44
▸ CYP1A2 P05177 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ ENPP3 O14638 1/20 0.42
▸ ENPP1 P22413 1/20 0.42
▸ ENPP2 Q13822 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5639084 0.87 RAB9A (0.54) KMT2AALDH1A1RAB9ANPC1KDM4E
SCHEMBL5638116 0.86 SMN1; SMN2 (0.50) KMT2AALDH1A1RAB9ANPC1KDM4E
SCHEMBL5640321 0.86 FPR1 (0.45) MAPTENPP3ENPP1ENPP2
SCHEMBL5638456 0.85 NPC1 (0.50) KMT2AALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL5637096 0.81 ALDH1A1 (0.52) KMT2AALDH1A1THRBALOX12RAB9A
SCHEMBL5637037 0.80 KMT2A (0.49) KMT2AALDH1A1THRBALOX12RAB9A
SCHEMBL5637034 0.80 KMT2A (0.49) KMT2AALDH1A1THRBALOX12RAB9A
SCHEMBL5638914 0.80 KMT2A (0.47) KMT2AALDH1A1RAB9ANPC1KDM4E
SCHEMBL5640528 0.73 COL1A1 (0.41) ALDH1A1KDM4EMAPTCYP2C19
SCHEMBL5637432 0.73 HTT (0.50) KMT2AALDH1A1RAB9ANPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220856-B2 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2007-05-22 — — US disclosed
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2004-04-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists CCR5, CXCR3, CCR2 KMT2A 3541/4885ALDH1A1 1286/4885THRB 814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback